Stocktoria

AtriCure, Inc. ATRC

Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2005-08-05 · LEI

AtriCure, Inc. (ATRC) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $534.5M at a -2.1% net margin.

Chart by TradingView
65/100
Stocktoria Quality Score · grade B
7/9
Piotroski F — financial health
3.44
Altman Z″ — distress risk · safe
Dividend yield · no dividend

Quality score trend · recomputed for each fiscal year

Piotroski F /9
4 4 4 2 3 4 3 6 4 7 2016201720182019202020212022202320242025
Altman Z″
-0.12 -0.56 2.33 -0.12 1.87 4.47 3.18 3.17 2.76 3.44 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$43.56 as of 2026-08-12 · +23.6% 1y
$27.67$43.5652-wk
Market cap USD$1.5B
Net margin 5y avg-3%
Return on equity 5y avg-3.7%
Beta1.26
Employees1,350

Analyst price target

$47.00 +7.9% vs last
· 8 analysts
target range $36.00 – $55.00

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Smart money · insiders, last 12 months

Insiders net sold -$226,600 on the open market · 2 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 90%
Net marginstronger than 49%
Return on equitystronger than 56%
Revenue growthstronger than 73%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 7/9 tests passed

Altman Z″ components · safe zone

ComponentValue
Working capital / assets0.368
Retained earnings / assets-0.632
EBIT / assets-0.014
Equity / liabilities3.032

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
ATRCAtriCure, Inc.7/93.44+14.9%
GKOSGLAUKOS Corp2/90.74+32.3%
BVSBioventus Inc.8/90.5435.9-0.9%
UFPTUFP TECHNOLOGIES INC7/9628.7+19.5%
ARAYACCURAY INC6/9-1.53+2.7%
AORTARTIVION, INC.7/93.05117.3+13.6%
MDXGMIMEDX GROUP, INC.5/98.0612+20%

All Manufacturing companies →

About AtriCure, Inc.

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

FAQ

Is ATRC financially healthy?

AtriCure, Inc.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does ATRC pay a dividend?

No, AtriCure, Inc. does not currently pay a dividend.

How profitable is ATRC?

In FY2025, AtriCure, Inc. had a net margin of -2.1% and a return on equity of -2.3%.

What is the analyst price target for ATRC?

The average Wall-Street price target for AtriCure, Inc. is $47.00, about 7.9% above the recent price, from 8 analysts.

Is ATRC a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on AtriCure, Inc.: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.